ABBV
Q1 came in hot
AbbVie’s first quarter looked a lot like a company showing up to a group project with three finished slides and a very smug smile. Sales hit $15.0 billion, topping Wall Street’s $14.72 billion target, while adjusted EPS landed at $2.65, also ahead of consensus.
The real engines: Skyrizi, Rinvoq, and friends
The headline wasn’t just “beat.” It was where the beat came from. Immunology brought in $7.29 billion, up 16.4%, with:
- Skyrizi sales jumping 30.9% to $4.48 billion
- Rinvoq climbing 23.3% to $2.12 billion
- Humira still fading, down 38.6% to $688 million
That’s the kind of mix shift investors like: the old blockbuster is shrinking, but the next generation is doing the heavy lifting instead of leaving a gap the size of a parking lot.
Neuroscience is doing its part too
AbbVie’s neuroscience portfolio was another bright spot, rising 26% to $2.875 billion. Vraylar grew 18.4% to $905 million, while Botox Therapeutics added 16.5% to $1.01 billion. Even the company’s cosmetic Botox business stayed lively, up 20.2% to $668 million.
Why the stock got a little pep in its step
The other big investor carrot: AbbVie raised its 2026 adjusted EPS guidance to $14.08-$14.28 from $13.96-$14.16. That’s not exactly a moonshot, but in pharma land, a guidance hike is basically the corporate version of saying, “Relax, we’ve got this.”
Big picture: AbbVie is still juggling Humira’s decline, but the new portfolio is growing fast enough to make the transition look less like a problem and more like a handoff.